XSTO
BOUL
Market cap9mUSD
Oct 09, Last price
2.42SEK
1D
2.98%
1Q
-36.48%
Jan 2017
-96.54%
IPO
-79.05%
Name
Boule Diagnostics AB
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, and Medonic brands; and veterinary hematology and clinical chemistry analyzer systems, as well as reagents and panels under the Exigo brand. It serves small and medium-sized hospitals, clinics, laboratories, and veterinary clinics, and other diagnostics firms. The company was founded in 1956 and is headquartered in Spånga, Sweden.
Related entities
Subsidiaries
Boule Medical AB
Key people
President, Chief Executive Officer · since 2020
Fredrik Ekdahl
Senior Vice President Research & Development · since 2017
Michael Elliott
Senior Vice President Research & Development at CDS
Debbie Herrera
Senior Vice President of Quality & Regulatory · since 2017
Hans Johansson
Senior Vice President of Production
Chief Financial Officer, Senior Vice President · since 2017
Kiarash Farr
Director of Commercial Operations · since 2018
Director · since 2014
Director · since 2018
Karin Dahllof
Independent Director · since 2015
Independent Director · since 2016
Headquarters & legal address
Fagerstagatan 7
SPÅNGA 163 53
SE
SPÅNGA 163 53
SE
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||